Ultrasound Guided Octreotide LAR Injection in Acromegaly

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Acromegaly
Interventions
DRUG

Octreotide LAR 30 MG Injection

Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER